Hikma Pharmaceuticals PLC (LON:HIK) Receives GBX 2,225 Average PT from Analysts

Hikma Pharmaceuticals PLC (LON:HIK) has been given a consensus rating of “Moderate Buy” by the six analysts that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is GBX 2,225 ($28.85).

Several equities research analysts recently commented on HIK shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 2,750 ($35.66) price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, June 18th. Berenberg Bank reissued a “hold” rating and set a GBX 2,000 ($25.94) price objective on shares of Hikma Pharmaceuticals in a research note on Thursday, April 25th. Finally, Barclays reissued an “equal weight” rating and set a GBX 2,000 ($25.94) price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, May 7th.

Insiders Place Their Bets

In other news, insider Riad Mishlawi bought 736 shares of the firm’s stock in a transaction on Tuesday, May 7th. The stock was acquired at an average cost of GBX 1,979 ($25.66) per share, with a total value of £14,565.44 ($18,889.17). Corporate insiders own 30.62% of the company’s stock.

Hikma Pharmaceuticals Trading Up 0.4 %

LON:HIK opened at GBX 1,867 ($24.21) on Friday. Hikma Pharmaceuticals has a one year low of GBX 1,711 ($22.19) and a one year high of GBX 2,222 ($28.82). The company has a debt-to-equity ratio of 53.92, a current ratio of 1.57 and a quick ratio of 1.27. The company’s 50-day simple moving average is GBX 1,923.14 and its 200 day simple moving average is GBX 1,911.35. The firm has a market capitalization of £4.14 billion, a P/E ratio of 2,786.57, a PEG ratio of 2.38 and a beta of 0.44.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.